Last reviewed · How we verify

NCT03467854

PK of Piperacillin/Tazobactam in Adults Undergoing ECMO

Terminated Last updated 26 September 2024
What this trial tests

trial in Acute Respiratory Failure With Hypoxia in 2 participants. Terminated before completion.

Timeline
1 January 2019
Primary endpoint
24 September 2024
24 September 2024

Quick facts

Lead sponsorColumbia University
StatusTerminated
Study typeOBSERVATIONAL
Enrollment2
Start date1 January 2019
Primary completion24 September 2024
Estimated completion24 September 2024
Sites1 location across United States

Conditions studied

Sponsor

Columbia University

Who can join

18 and older, any sex, with Acute Respiratory Failure With Hypoxia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is designed to provide preliminary data to determine if concentrations of piperacillin/tazobactam change in patients with severe respiratory failure receiving extracorporeal membrane oxygenation (ECMO). The investigators hypothesize that patients will have significant changes in concentration measurements, specifically an increased clearance rate and increased volume of distribution, during ECMO as compared to critically ill patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Acute Respiratory Failure With Hypoxia

Currently open trials in the same condition.

Other Columbia University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03467854.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing